ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Inadequate Overall Immunosuppression Is a Risk for Late Acute Rejection Despite Alemtuzumab Induction in Simultaneous Pancreas Kidney Transplant Recipients

J. Bank,1 M. Mallat,1 P. van der Boog,1 D. Braat,2 J. Ringers,2 M. Vergunst,3 S. Heidt,3 F. Claas,3 M. Reinders,1 J. de Fijter.1

1Nephrology, LUMC, Leiden, Netherlands
2Surgery, LUMC, Leiden, Netherlands
3IHB, LUMC, Leiden, Netherlands.

Meeting: 2015 American Transplant Congress

Abstract number: C195

Keywords: Immunosuppression, Induction therapy, Pancreas transplantation, Rejection

Session Information

Session Name: Poster Session C: More Controversies in Pancreas Transplantation

Session Type: Poster Session

Date: Monday, May 4, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Introduction: Simultaneous pancreas-kidney transplantation (SPK) has become the treatment of choice for patients with end-stage renal disease due to Type 1 Diabetes Mellitus. SPK is associated with a relative high rate of acute rejections (AR) compared to kidney transplantation alone. Previously, we showed that a steroid-free regime with Alemtuzumab induction significantly reduced AR rates compared to ATG. Here we investigated time to and risk factors for rejection including inadequate overall immune suppression. In addition, we evaluated whether repopulation with specific alloreactive immune cells is associated with rejection. Methods: 158 SPK recipients were included, and current induction therapy Alemtuzumab (n=73) was compared to historical controls treated with ATG (n=85). Maintenance therapy consisted of Tacrolimus, MMF and, in case of ATG, Prednisone. Data regarding trough levels, immunosuppressive therapy and side effects were collected retrospectively. Peripheral blood was obtained from 30 patients (13 at time of AR,17 controls) for mixed lymphocyte cultures (MLC) and flow cytometric analysis of immune cells. Results: A significant decline in AR rate was seen in the Alemtuzumab group (20.5%) compared to ATG (43.5%). There was no difference in the amount of infections, immunizations or Tacrolimus trough levels between both groups. Within the ATG group 94.6% of the AR occurred within 30 days. In contrast, with Alemtuzumab a biphasic distribution was seen, 20% of the AR occurring within 30 days and 80% after 90 days. In the ATG group, 3 out of 37 patients had inadequate trough levels prior to AR, however in most patients no identifiable cause was found. With Alemtuzumab, most AR (10 out of 15) were related to adjustments of immunosuppressives due to viral infections, leukopenia and gastrointestinal symptoms. Preliminary MLC results in the latter group showed repopulation without a difference in alloimmune reactivity between stable and rejecting patients. Conclusion: In SPK recipients, Alemtuzumab induction significantly reduced AR rates and showed a biphasic distribution. Rejection was attributable to adjustments of immunosuppressives in the majority of the patients. Therefore a reduction in immunosuppressives at the time of repopulation of immune cells must be carefully considered.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Bank J, Mallat M, Boog Pvander, Braat D, Ringers J, Vergunst M, Heidt S, Claas F, Reinders M, Fijter Jde. Inadequate Overall Immunosuppression Is a Risk for Late Acute Rejection Despite Alemtuzumab Induction in Simultaneous Pancreas Kidney Transplant Recipients [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/inadequate-overall-immunosuppression-is-a-risk-for-late-acute-rejection-despite-alemtuzumab-induction-in-simultaneous-pancreas-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences